• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

72.76 -5.05 (-6.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 854,173
Open 77.35
Bid (Size) 72.37 (100)
Ask (Size) 72.85 (100)
Prev. Close 77.81
Today's Range 72.16 - 77.83
52wk Range 19.45 - 103.00
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks ↗
January 01, 2026
Via MarketBeat
News headline image
Streaming Wars Go Hostile Just as Wall Street Braces for the Fed ↗
December 09, 2025
Stocks slipped from record levels on Monday as investors shifted into “wait-and-see” mode ahead of Wednesday’s Fed decision. At the same time, Hollywood turned into a live-fire M&A battlefield, with... 
Via Chartmill
Topics Economy

Performance

YTD
N/A
N/A
1 Month
+9.2%
+9.2%
3 Month
+26.4%
+26.4%
6 Month
+66.1%
+66.1%
1 Year
+82.4%
+82.4%

More News

Read More
News headline image
What's going on in today's session ↗
December 08, 2025
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
December 08, 2025
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
Via Benzinga
News headline image
What to Expect from Kymera Therapeutics's Earnings ↗
August 08, 2025
Via Benzinga
News headline image
Wondering what's happening in today's pre-market session? ↗
December 08, 2025
Via Chartmill
News headline image
Why Is KYMR Stock Up 30% Pre-Market Today? ↗
December 08, 2025
Via Stocktwits
Topics Economy
News headline image
These stocks are moving in today's after hours session ↗
December 05, 2025
Via Chartmill
News headline image
Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Earnings
News headline image
10 Analysts Have This To Say About Kymera Therapeutics ↗
November 05, 2025
Via Benzinga
News headline image
Kymera Therapeutics Inc (NASDAQ:KYMR) Q3 2025 Earnings: Clinical Progress Overshadows Financial Miss ↗
November 04, 2025
Via Chartmill
News headline image
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts ↗
October 17, 2025
Via Benzinga
News headline image
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views ↗
September 16, 2025
Via Benzinga
News headline image
This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
September 16, 2025
Via Benzinga
News headline image
Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market ↗
August 11, 2025
Via Chartmill
Topics Earnings
News headline image
Kymera Revenue Drops 55 Percent in Q2 ↗
August 11, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' ↗
July 09, 2025
Via Benzinga
News headline image
Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock ↗
June 26, 2025
Via Benzinga
News headline image
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday ↗
June 26, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2025 ↗
August 11, 2025
Via Benzinga
News headline image
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit ↗
June 25, 2025
Via Stocktwits
News headline image
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies ↗
June 25, 2025
Via Benzinga
News headline image
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
June 25, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
June 12, 2025
Via MarketBeat

Frequently Asked Questions

Is Kymera Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kymera Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kymera Therapeutics, Inc. - Common Stock trade on?
Kymera Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kymera Therapeutics, Inc. - Common Stock?
The ticker symbol for Kymera Therapeutics, Inc. - Common Stock is KYMR on the Nasdaq Stock Market
What is the current price of Kymera Therapeutics, Inc. - Common Stock?
The current price of Kymera Therapeutics, Inc. - Common Stock is 72.76
When was Kymera Therapeutics, Inc. - Common Stock last traded?
The last trade of Kymera Therapeutics, Inc. - Common Stock was at 01/02/26 04:00 PM ET
What is the market capitalization of Kymera Therapeutics, Inc. - Common Stock?
The market capitalization of Kymera Therapeutics, Inc. - Common Stock is 4.02B
How many shares of Kymera Therapeutics, Inc. - Common Stock are outstanding?
Kymera Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap